<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00210444</url>
  </required_header>
  <id_info>
    <org_study_id>A-38-52120-714</org_study_id>
    <nct_id>NCT00210444</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Dysport® in the Treatment of Anal Fissure.</brief_title>
  <official_title>A Phase II, Multicentre, Open, Randomised, Parallel Group, Dose Ranging Study to Define the Efficacy of Dysport® in the Treatment of Anal Fissure.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <brief_summary>
    <textblock>
      To evaluate the effect on healing rates of two different prognostic factors in patients
      treated with Dysport® for anal fissure: duration of fissure and dose of study drug
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Healing of the anal fissure by complete re-epithelisation of the anal canal mucosa.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of anal pain measured by the patients on Analogue Visual Pain Scale.</measure>
  </secondary_outcome>
  <enrollment>152</enrollment>
  <condition>Anal Fissure</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin type A (Dysport)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients having idiopathic anal fissure in the posterior anal midline

          -  Patients having anal fissure present for less than 6 months

          -  Patients having symptoms (pain) present for a minimum of 2 weeks and not responding
             after 2 weeks of standard therapy (diet, laxatives, sitz-bathes)

        Exclusion Criteria:

          -  Patients having anal fistulas or anal fissure of various causes such as Crohn disease,
             Behcet infectious ulceration, anal suppuration, subfissural infiltration, abscesses,
             acute haemorrhoidal attacks or inflammatory bowel disease

          -  Patients having idiopathic anal fissure in the anterior anal midline

          -  Patients having lateral or multiple fissures

          -  Patients having anal or perianal cancer

          -  Patients who underwent previous anal surgery or have cicatricial alterations or
             post-surgical cicatricial lesions

          -  Patients receiving drugs affecting neuromuscular transmission

          -  Patients who have received topical anaesthetic within 3 days of injection

          -  Patients receiving local treatment by myorelaxing agent

          -  Patients receiving prohibited analgesics

          -  Patients having bleeding disturbances or currently using coumarin derivates

          -  Patients having myasthenia or any genetic muscle disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Lempereur, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty Nemocnice-III</name>
      <address>
        <city>Brno</city>
        <zip>639-01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty Nemocnice</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500-05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomayer's Memorial Hospital</name>
      <address>
        <city>Prague</city>
        <zip>140-59</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consulting Room of Proctology</name>
      <address>
        <city>Gdansk</city>
        <zip>80-371</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Lodz</name>
      <address>
        <city>Lodz</city>
        <zip>90-447</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute Clinique Fundeni</name>
      <address>
        <city>Bucharest</city>
        <zip>Sector 2</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hopital Charles Nicolle de Tunis</name>
      <address>
        <city>Tunis</city>
        <zip>1006</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2005</study_first_submitted>
  <study_first_submitted_qc>September 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>September 12, 2007</last_update_submitted>
  <last_update_submitted_qc>September 12, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fissure in Ano</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

